Elevated expression of the integrin-linked kinase (ILK) has been observed in a variety of cancers and has been further correlated with poor clinical outcome. Here, we show that mammary epithelial disruption of ILK results in a profound block in mammary tumor induction. Consistent with these observations, inhibition of ILK function in ErbB2-expressing cells with small molecule inhibitor or RNA interference resulted in profound block in their in vitro invasive properties due to the induction of apoptotic cell death. The rare ILK-deficient tumors that eventually arose overcame this block in tumor induction by an upregulation of ErB3 phosphorylation. These observations provide direct evidence that ILK has a critical role in the initiation phase of ErbB2 tumor induction.
Introduction
The integrin-linked kinase (ILK) is a modular protein with separate scaffolding and kinase-like domains that mediates the physical and functional coupling of integrins to growth factor signaling (Hannigan et al., 2005; McDonald et al., 2008a) . ILK modulates integrinmediated adhesion by directly interacting with the cytoplasmic tails of b1-or b3-integrin receptors (Hannigan et al., 1996) , and complexes with Parvin A/B (Attwell et al., 2003; Mongroo et al., 2004) and PINCH (Tu et al., 1999) . More recently, ILK has also been shown to have an instrumental role in the proper organization of the mitotic spindle during cell division (Fielding et al., 2008) . In addition to these critical scaffold functions, ILK can modulate a number of cell survival and proliferation signaling pathways, including the AKT/GSK3 pathway and mTOR signaling. ILK is involved in the phosphorylation of two serine/threonine kinases, GSK3b and Akt1 (Delcommenne et al., 1998) . ILK-mediated phosphorylation of GSK3 results in GSK3b auto-inhibition, and the consequent stabilization of b-catenin and cyclin D1 (Radeva et al., 1997; D'Amico et al., 2000) . Whereas ILK-induced AKT phosphorylation on its serine residue S473 increases cell survival by promoting anoikis resistance , phosphorylation of this residue also induces VEGF-dependent angiogenesis in cancer cell lines (Tan et al., 2004) . Conversely, inhibition of ILK or ILK-PINCH function markedly decreases AKT phosphorylation in number of normal and cancer cell lines (Persad et al., 2000; Fukuda et al., 2003a Fukuda et al., , 2003b Hannigan et al., 2005; Koul et al., 2005; Younes et al., 2005; Troussard et al., 2006) . Recent data have also shown that ILK functionally interacts with mTORC2 (Troussard et al., 2006) , through a direct interaction with Rictor, a component of the mTOR complex 2 (McDonald et al., 2008b) . Taken together, these observations suggest that ILK may mediate its effects through multiple distinct molecular pathways.
Direct evidence of the importance of ILK in mammary tumor progression derives from studies with transgenic mice. Mammary epithelial expression of ILK in transgenic mice using the MMTV promoter is associated with the induction of mammary epithelial hyperplasias that rarely progress to full malignancy (White et al., 2001) . Interestingly, the tumors that eventually occur in these strains exhibit hallmarks of epithelial to mesenchymal transition (EMT) and no longer productively express the transgene but express elevated levels of the endogenous ILK gene (White et al., 2001) .
Whereas these studies implicate elevated ILK expression in mammary tumor progression, its role in cancers induced by activated growth factor receptors such as ErbB2 is unclear. To investigate the role of ILK in ErbB2 tumor progression, we have assessed the effect of the targeted disruption of ILK in mammary epithelium on both normal mammary development and ErbB2 tumor progression. To accomplish this, we have interbred mice bearing a conditional ILK allele (Terpstra et al., 2003) to separate transgenic mice co-expressing ErbB2 and Cre recombinase in the mammary epithelium (Ursini- Siegel et al., 2008) . Although mammary epithelial disruption of ILK had little impact on normal mammary gland development (Supplementary Figure S1A) , loss of ILK function in ErbB2-expressing epithelium resulted in a profound proliferative block that was correlated with a dramatic impact in ErbB2 tumor onset and penetrance. However, the rare ILK-deficient tumors that eventually arose regained their capacity to proliferate that was correlated with dramatic upregulation of ErbB3 tyrosine phosphorylation. Finally, using an in vitro dissemination assay, we show that abrogation of ILK function in established ErbB2 mammary tumor cells results in block in invasion that was further correlated with induction of apoptotic cell death. Collectively, these observations suggest that ILK has a critical role in ErbB2 mammary tumor progression.
Results
Targeted disruption of ILK in mammary epithelium expressing activated ErbB2 results in a dramatic delay in mammary tumor development To determine the effects of ILK deletion on normal mammary gland development, we interbred mice carrying the conditional ILK alleles to a separate strain of mice expressing the Cre recombinase under the control of the MMTV promoter ( Figure 1a) . To confirm the loss of ILK expression in the mammary epithelium of mice bearing the conditional ILK allele, we performed immunofluorescence with ILK-, Cre-and Keratin 8-specific antibodies on paraffin-embedded sections of mammary glands derived from 6-week-old female mice (Figure 1b To ascertain whether loss of ILK function in mammary epithelial compartment was associated with any developmental defect, we next assessed whether the initial stages of ductal outgrowth were affected by performing wholemount analyses on both control ILK f/f or MMTV-CRE/ILK f/f mammary glands from 5 to 8 weeks of age (Supplementary Figure S1A) . Given the documented mosaic expression of Cre in the mammary gland of the MMTV/Cre strain, we also introduced into these crosses, the Cre-inducible ROSA26 b-galactosidase reporter (Soriano, 1999) . Although the whole-mount analyses revealed no obvious defect in the initial stages of ductal outgrowth (Supplementary Figure S1A) , comparison of b-galactosidase staining of the MMTV-CRE/ILK f/f mammary glands between 6-and 8-weekold samples revealed that extent of excision was dramatically reduced during these two time points (Figure 2c ). These observations indicate that the ILKdefective epithelial cells are selectively lost during these two developmental time points. To monitor precisely the extent of the disappearance of ILK-deficient cells in the mammary gland later in the development, we performed FACS analysis on Cre/ILK f/f mammary glands also expressing a Cre-inducible green fluorescent protein (GFP) marker (Kawamoto et al., 2000) . Consistent with previous results, at 10 weeks of age, although 20% of the mammary gland epithelial cells (defined as Lin -) were GFP-positive in control mammary glands, only 4% of epithelial cells were GFP-positive in a Cre/ILK f/f genetic background. This amount was further reduced at 15 weeks ( Figure 2d ). Collectively, these observations suggest that ILK-deficient mammary epithelial cells are selectively lost during these early stages of mammary gland development.
Previous studies have shown elevated expression of ILK in number of human cancers (McDonald et al., 2008a) . Consistent with this view, immunohistochemical analysis of mammary tumors derived from transgenic mice expressing activated ErbB2 under the transcriptional control of the MMTV promoter with ILK-specific antibodies revealed that they expressed elevated levels of ILK protein (Figure 3a , NIC ILK wt/wt panel). To determine if ILK expression is required for the induction of mammary tumors in these MMTV/activated ErbB2 transgenic mice (NIC strain), we introduced the conditional ILK alleles into this strain. We have previously shown that the MMTV/NIC strain develops metastatic mammary tumors with comparable latency to other MMTV/activated ErbB2 strains (Ursini- Siegel et al., 2008) . Because NIC transgene also co-express Cre recombinase due to the presence of internal ribosome entry site (IRES), mammary epithelial cells expressing activated ErbB2 will excise the conditional ILK allele (Ursini- Siegel et al., 2008) . Thus the coupled expression of ErbB2 and Cre recombinase precludes the possibility of obtaining ErbB2-expressing Crenegative 'escapee' populations that could possibly contribute to the tumor. Indeed, we successfully showed that this approach results in complete ablation of targeted allele in NIC mice harboring either Stat3 or ShcA conditional alleles (Ursini- Siegel et al., 2008; Ranger et al., 2009) .
Using this approach, we generated cohorts of female mice expressing the NIC transgene that were either homozygous or heterozygous for the conditional ILK allele. Heterozygous mice developed multifocal mammary tumors with a similar latency period as that of wild-type controls; homozygous mice, however, developed focal mammary tumors only after a long delay and with dramatically decreased penetrance (Figure 2a) . Significantly, only 56% of female cohort carrying both conditional alleles developed mammary tumors after a year observation period. The observed delay in ErbB2-induced tumors in mice homozygous for the conditional ILK alleles was further correlated with the efficient Cre-mediated excision of the conditional ILK alleles (Figure 2b , Tumor 1-6), and marked reduction of ILK protein levels in premalignant mammary epithelium (Figure 2c ) or ILK-deficient tumors from the NIC strain ( Figure 3a , NIC ILK f/f panel). Given the dramatic reduced incidence of tumor induction and focal nature of these tumors, these observations suggest that ILK has a critical role in ErbB2-induced tumor progression.
To ascertain whether the block in tumor progression was due to decrease in proliferative capacity, we next investigated whether pre-malignant mammary epithelium expressing activated ErbB2 was compromised in its proliferative status. To accomplish this, we subjected sections derived from premalignant mammary glands at Figure S2) . To identify those cells that had undergone Cre-mediated recombination of the conditional ILK allele, we also co-stained these sections with antibodies directed toward Cre recombinase. The results revealed that Cre expressing mammary epithelium derived from NIC mice bearing both ILK conditional alleles were severely compromised in their proliferative capacity compared to their wild-type counterparts ( Figure 2d , Supplementary Figure S2 ). Indeed, quantitative evaluation of number of independent sections revealed that ILK-deficient mammary epithelial cell exhibited a 10-fold reduction in their proliferative capacity as indicated by their Ki-67 to Cre expressing ratio ( Figure 2d , right panel). These results suggest that targeted disruption of ILK leads to profound proliferative deficit indicating that the block in mammary tumor induction may be partly due to the decreased proliferative capacity of these cells.
ILK-deficient tumor cells have regained their proliferative signaling capabilities
Though mammary-specific deletion of both alleles of ILK resulted in an increased latency period and reduced tumor penetrance in the MMTV-activated ErbB2 mice, focal mammary tumors were eventually observed in 56% of susceptible female animals. To confirm that loss of ILK alleles correlated with loss of ILK protein, we performed immunohistochemistry on ILK-deficient tumors with ILK antisera. Although ILK staining was observed in stromal tissues (Figure 3a ), the bulk of the Keratin 8-positive tumor epithelia bearing both conditional ILK alleles failed to stain with ILK ( Figure 3c ) indicating that these ErbB2-induced tumors were ILK deficient.
To ascertain whether the ILK-deficient tumors exhibited proliferative defect, we next assessed the proliferative status of these tumors by immunostaining with both Cre-and Ki-67-specific antisera. By contrast to premalignant ErbB2-expressing tissue that exhibited a profound proliferative block ( Figure 2d , Supplementary Figure S2 ), the ErbB2-expressing tumors exhibited a high proliferative capacity despite the absence of ILK protein ( Figure 3b ). These observations suggest that these ErbB2 ILK-deficient tumor cells have selected alternative signaling pathways that circumvented the requirement of ILK for epithelial cell proliferation.
To identify the nature of alternative signaling network, we next examined whether the ILK-deficient tumors exhibited any obvious defects in signaling pathways that are thought to be regulated by ILK. To accomplish this, we used both reverse-phase protein analyses and immunoblot analyses with phosphospecific antibodies directed at these key downstream signaling molecules (Hennessy et al., 2007) . The results revealed that the rare ILK-deficient tumors that arise did not show a significant decrease in signaling through any of these core signaling pathways (Supplementary Figure S3 and S4). Taken together, these observations suggest that ILK-deficient tumors have adapted to induce these signaling pathways in an ILK-independent manner.
ILK deletion impairs signaling and metastasis of ErbB2-expressing tumor cells
Another important function of ILK is to modulate integrin-dependent adhesion (Dedhar et al., 1999) . To assess whether activation of integrin-dependent signaling was affected by deletion of ILK, we next performed immunoblot analyses with a number of antibodies directed against integrin-coupled signaling molecules, including paxillin and Cas ( Figure 4a ). The results revealed that the tyrosine phosphorylation levels of Cas and paxillin were dramatically decreased in ILKdeficient ErbB2-expressing tumors (Figure 4a ). The differences in tyrosine phosphorylated Cas and paxillin were not due to changes in protein levels. In fact, the levels of p130Cas were considerably higher in the ILKdeficient tumors (Figure 4a ), arguing that tyrosine phosphorylation of p130Cas may be important in p130Cas protein stability. These data suggest that ILK behaves as a scaffold coupling of p130Cas and paxillin to activated c-Src (Figure 4a) . Interestingly, the ILKdeficient ErbB2-expressing tumors have a dramatic increase in the tyrosine phosphorylation levels of ErbB3 as compared to wild-type tumors (Figure 4a ). Given the documented ability of ErbB3 to activated the phosphatidylinositol-3-kinase signaling pathway, it is conceivable that this selective upregulation of ErbB3 signaling functionally compensates for lack of ILK function. Consistent with this, we observed that despite the tumor onset delay and decreased penetrance of the ILKdeficient mice, the tumors had comparable proliferative and growth defects (Figures 3b and 4b) .
Given the marked defects in adhesion signaling observed in ILK-deficient ErbB2 tumors, we next investigated whether loss of ILK impacted on the metastatic capacity of the ILK-deficient ErbB2 tumors. Although 67% (8 mice out of 12) of NIC ILK wt/wt mice developed metastatic lung lesions, only 45% (5 mice out of 11) of NIC ILK f/wt and 43% (9 mice out of 21) of NIC ILK f/f mice exhibit metastasis to the lung (Figure 4c ). Although the effects of ILK ablation had a modest impact on spontaneous metastasis, injection of ILKdeficient ErbB2 tumors into tail veins of immunodeficient mice revealed a dramatic defect in capacity to colonize the lung (Supplementary Figure S1C) , suggesting loss of adhesion signaling may influence the capacity of ILK-deficient cells to colonize the lung.
Pharmacological inhibition of ILK in established ErbB2 tumors impairs their in vitro invasive properties
Although the above studies suggest that ILK function is required for the initiation of ErbB2 tumor progression, whether ILK function impacted on the invasive properties of established tumor cells was unclear. To further investigate this issue, we developed a novel threedimensional assay of local tumor dissemination. In this assay, MMTV-ErbB2-derived tumor cells are cultured on a thick bed of Matrigel-reconstituted basement membrane where they form solid, multicellular aggre- gates that recapitulate the three-dimensional architecture and histological features of MMTV-ErbB2-derived mouse mammary tumors (Figures 5a and c, inset) . These structures are noninvasive and resemble ductal carcinoma in situ-like lesions, exhibiting well-defined margins and prominent E-cadherin expression at cell-cell junctions ( Figure 5c and data not shown). Given the documented pro-invasive role of collagen in advanced human breast cancer (Provenzano et al., 2006) , we chose to overlay a collagen I matrix on this Matrigel plug. Once the margins of these ductal carcinoma in situ-like acini contact the overlay of connective tissue-derived fibrillar collagen I, individual tumor cells invade and disseminate throughout the collagen I gel (Figures 5b and d) . The observed disruption of the acini margins and the loss of cell-cell adhesive junctions in the presence of collagen I resemble the EMT that is correlated with tumor invasion.
To investigate the role of ILK in this in vitro invasion assay, we used both RNA interference and small molecule inhibitors directed against ILK. One small molecule inhibitor that has been used to target ILK is QLT0267. This second-generation ILK inhibitor inhibits the kinase activity of ILK and it exhibits a high degree of selectivity against a wide panel of protein kinases (Troussard et al., 2006) . Using this in vitro invasion assay, we showed incubation of the tumor cells with 10 mM QLT0267 impaired invasion into the collagen I gel (Figure 5e ). To ensure that observed effects on tumor invasion were specific to ILK, we also used RNA interference approach to directly downregulate ILK in these ErbB2 tumor cells. Consistent with small molecule inhibitor studies, we observed impaired invasion after shRNA-directed knockdown of ILK mRNA and protein expression (Figure 5f, Supplementary Figure S5 ). Taken together, these observations suggest that ILK has a role in the local invasion of MMTV-ErbB2-derived tumor cells during the early stages of metastasis.
Hematoxylin/eosin-stained sections of untreated control cultures confirmed that collagen I promoted an EMT-like transition to an invasive, elongated tumor cell phenotype (Figures 5g and h ). The same transition was not observed, however, when the cells were presented with collagen I in the presence of QLT0267 (Figure 5i ). In contrast, disseminated cells in the treated culture appeared small and pyknotic, characteristic of cells undergoing apoptotic cell death (Figure 5i and inset, arrows). The presence of pyknotic nuclei in cells undergoing invasion was also observed after expression of an shRNA construct targeting ILK expression (Figure 5j, arrow) . The apoptotic nature of these cells was confirmed by subjecting sections to the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. As shown in Figure 5k , disseminated cells in the QLT0267-treated culture stained positive for apoptotic nuclei (Figure 5k, arrows) . In contrast, the parental control cells undergoing invasion exhibited little evidence of positive TUNEL staining, consistent with their robust nuclei and abundant cytoplasm (Figure 5l ). Quantitative analysis of several independent experiments revealed that 71 ± 15.5% of the disseminated cells in the QLT0267- treated culture exhibited apoptotic nuclei after 48 h, compared to 12±6.2% of the disseminated cells in the untreated control culture (Po0.0036; unpaired t-test).
Interestingly, QLT0267-treated cells in Matrigel exhibited no evidence of apoptotic cell death by hematoxylin/eosin staining (Figure 5m ) or TUNEL staining (Figure 5n ) of sections after 48 h incubation. This difference in sensitivity to QLT0267-induced cell death of cells in Matrigel alone vs the pro-invasive collagen I overlay was not due to differences in the proliferation index (data not shown). Because Matrigel promotes solid tumor-like growth, as opposed to disseminated cells, this observation is consistent with the growth of solid mammary tumors observed in the ILK-deficient ErbB2 tumors. Taken together, these results suggest that ILK-deficient or QLT0267-treated ErbB2 tumor cells are sensitized to apoptotic cell death in this in vitro model of local invasion and metastatic dissemination.
Discussion
An increasing body of evidence implicates integrin signaling as a critical component of both normal mammary gland development and mammary tumor progression. For instance, the targeted disruption of b1-integrin has been shown to affect both the late stages of mammary gland differentiation (Li et al., 2005) and mammary tumorigenesis (White et al., 2004) . Central integrin signaling effectors, such as FAK, have also been shown to participate in tumor progression (Lahlou et al., 2007) , though these are not involved in normal mammary gland development in either the early (Lahlou et al., 2007) or late (Akhtar et al., 2009 ) stages of development. Here we show that similar to FAK, ILK has a critical role in the initiation phase of tumor development. Although ILK-deleted cells appear to participate normally in the initial developmental phases of the mammary epithelium, ILK is essential for terminal mammary gland differentiation, because its targeted deletion affects both alveologenesis and lactogenesis (Akhtar et al., 2009) . The importance of ILK in these aspects of mammary gland development may reflect its central role in integrating signaling from growth factors and integrin receptors. Indeed, ILK is known to associate with linker molecules such as PINCH that in turn can associate with the receptor tyrosine kinase Nck adaptor protein (Tu et al., 1999) . In addition to its critical role in lateral cross talk between growth factor receptors, ILK is also involved in activating key survival and proliferative signaling pathways such as Akt1/PKBa and GSK3b (Delcommenne et al., 1998; D'Amico et al., 2000; White et al., 2001) . In this regard, we have shown that targeted disruption of ILK in the heart results in a dramatic impact on both MAPK and Akt1/PKBa phosphorylation .
Although ILK is dispensable for the initial stages of mammary outgrowth, elevated expression of ILK has been implicated in mammary tumor progression. We have previously shown that ectopic expression of ILK results in induction of metastatic mammary tumors that possess the hallmarks of an EMT phenotype (White et al., 2001) . Using an ErbB2 transgenic model (Ursini- Siegel et al., 2008) , we have shown that mammary epithelial disruption of ILK resulted in a dramatic delay in mammary tumor induction. Analyses of premalignant ErbB2-expressing mammary epithelium lacking ILK function has revealed that this block in ErbB2 tumor induction is associated with profound block in epithelial proliferation (Figure 2d, Supplementary Figure S2) . However, the rare ILK-deficient ErbB2-expressing tumors that eventually arose exhibited equivalent proliferative capacity to their ILK proficient counterparts. In addition, phosphorylation levels of both Akt/PKBa and MAPK proteins were comparable in the control and ILK-deficient tumors, suggesting that ILK is not required to activate these two pathways in the ErbB2-driven tumor signaling network. Consistent with these analyses, reverse-phase protein analyses with a large number of phospho-specific antibodies failed to reveal significant differences in several well-characterized signaling pathways (Supplementary Figure S3) . These observations suggest that ILK-deficient ErbB2-expressing tumors evolved alternative mechanisms to activate these critical downstream signaling pathways. In this regard, we have observed an increased activation of the ErbB3 pathway (Figure 4a ) that may potentially compensate for loss of ILK function. Indeed, elevated ErbB3 signaling has been implicated in resistance to epidermal growth factor receptor inhibitors in lung cancer (Engelman et al., 2005 (Engelman et al., , 2007 Turke et al., 2010) . Given ErbB3's documented role in activation of the phosphatidylinositol-3-kinase signaling pathway Soltoff et al., 1994) , elevated activation of phosphatidylinositol-3-kinase pathway is likely responsible for circumventing the requirement for ILK.
Although ILK appears dispensable for the activation of these key proliferative signaling pathways, its loss still induced major defects in other integrin-coupled signaling pathways. In particular, tyrosine phosphorylation of paxillin and p130Cas, but not Src, were compromised in ILK-deficient tumor cells. These observations suggest that ILK may also have a key scaffold role in activation of paxillin and Cas. The loss of adhesion signaling network was further associated with reduction in the spontaneous metastatic burden in these mice (Figures 4b  and c) . Consistent with this reduction in spontaneous metastasis, injection of ILK-deficient tumor cells into tail veins of immunodeficient mice resulted in a dramatic reduction in the metastatic burden (Supplementary Figure S1B and C). Taken together, these observations suggest that ILK-dependent activation of this key adhesion signaling network may also have a role in the metastatic phase of ErbB2 tumor progression.
This diminished integrin signaling observed in ILKdeficient tumors is reminiscent of PyV mT tumors lacking FAK (Lahlou et al., 2007; Provenzano et al., 2008) . These tumors exhibit a complete block in metastasis (Lahlou et al., 2007; Provenzano et al., 2008) that correlates with downregulation of phosphop130Cas (Provenzano et al., 2008) . However, unlike ILK-deficient tumors, disruption of FAK results in the induction of hyperplastic or adenoma lesions that do not progressed to full malignancy (Lahlou et al., 2007; Provenzano et al., 2008) .
Previous studies have suggested that metastatic progression may involve transient EMT that facilitates the migratory behavior of cancer cells (Cowin and Welch, 2007) . In this regard, it is interesting to note that elevated expression of ILK in either established mammary epithelial cell or primary mammary epithelial cells is associated with an EMT phenotype (Somasiri et al., 2001; White et al., 2001) . In an established mouse model that typically displays a 100% penetrance, we have shown that the deletion of ILK delays the mammary gland tumorigenesis; in fact almost half of the female cohort did not develop any tumor. This phenotype is consistent with the reduced proliferation of these cells (Figure 2d, Supplementary Figure S2 ). Consistent with these observations, we have shown that in normal mammary gland development, ILK-deficient epithelial cells are at competitive disadvantage compared to their wild-type counterparts and thus are lost during mammary gland outgrowth (Figures 1c and d) . Collectively, these data argue that ILK function has a critical role in the induction of ErbB2 tumors.
Although the studies outlined above clearly show an important role for ILK in the initiation of mammary tumor progression, disruption of ILK function through either a small molecule inhibitor or RNA interference in established ErbB2 tumor cells can impact on their ability to invade in an in vitro metastasis assay ( Figure 5 ). However, unlike the proliferative block observed in the initiation phase of ErbB2 tumor induction, the inability to invade correlates with induction of apoptosis ( Figures  5j and k) . Given the importance of ILK in EMT, it is conceivable that mammary-specific ablation of ILK interferes with this critical phase of tumor metastasis. The association of EMT with metastatic phenotype in ErbB2 tumor induction is further supported by the observation that other modulators of the EMT phenotype such as TGFb can have a profound impact on ErbB2 tumor metastasis (Siegel et al., 2003) . Given the importance of metastasis in the morbidity of cancer, the development of therapeutic agents that impact on these key integrin-coupled signaling pathways such as ILK may prove to be attractive option for the treatment of metastatic breast cancer. (all from Cell Signaling, Danvers, MA, USA); anti-b-actin (Sigma) and anti-cyclin D1 (Santa Cruz Biotechnology). The antisera directed against b1-integrin, paxillin, p130Cas and antibromodeoxyuridine have been purchased from BD Biosciences (San Jose, CA, USA). Guinea pig polyclonal anti-cytokeratin 8/18 was purchased from Fitzgerald (Acton, MA, USA). The Alexa Fluor goat anti-guinea pig 488; anti-mouse 555 and 633; anti-rabbit 555 and 633 antibodies were from Molecular Probes (Eugene, OR, USA).
Materials and methods

Antibodies
Transgenic mice MMTV-Neu-IRES-CRE (NIC), MMTV-CRE and ILK flox mice were generated and characterized previously (Andrechek et al., 2000; Terpstra et al., 2003; Troussard et al., 2003; Ursini-Siegel et al., 2008) GTRosa26 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). The CAG-CAT-EGFP reporter mice were described previously (Kawamoto et al., 2000; Ahmed et al., 2002) . To preclude the possible involvement of genetic background variability, we derived all transgenic mice used from the inbred FVB/N strain. Mammary tumor formation was monitored in virgin mice by weekly palpations. For in vivo tumorigenesis assays performed with primary cultured cells, we injected 2.5 Â 10 5 cells in the inguinal fat pad of Ncr nude mice (NIH). Tumor progression was monitored twice a week and animals were killed at equivalent tumor volumes. All animal studies were approved by the Animal Resources Centre at McGill University and complied with the guidelines set by the Canadian Council of Animal Care.
Histological, immunohistochemical and immunohistofluorescence analyses After necropsy, mammary glands, tumors and lungs were fixed in 10% neutral buffered formalin (Surgipath, Richmond, IL, USA) and transferred to 70% ethanol the next day. Samples were then paraffin-embedded and sectioned at 4 mm. Mammary gland tumors and lungs were identified by microscopic analyses of hematoxylin/eosin-stained sections. Whole-mount and in situ b-galactosidase assays were performed on inguinal mammary glands as described by White et al. (2004) . For metastasis analysis, we observed five step sections separated by 50 mm and counted extra-or intravascular metastases. For immunohistochemistry or immunohistofluorescence analysis, we blocked endogenous peroxidase activity with 3% peroxide hydrogen in methanol. Antigen retrieval was accomplished in citrate buffer by using a pressure cooker (Cuisinart, WoodBridge, Ontario, Canada). Sections were then blocked with Power Block Universal Blocking Agent (BioGenex, San Ramon, CA, USA) and incubated in primary antibody as described by White et al. (2004) . For immunofluorescence analyses, we incubated sections with secondary antibodies for 1 h at room temperature and visualized with a Zeiss (Toronto, Ontario, Canada) LSM 510 META confocal microscope.
Mammary gland cell dissociation, primary cell cultures and FACS analysis Mammary gland fat pads were chopped three times with a McIlwain Tissue Chopper (Mickle Laboratory Engineering Company, Gomshall, Surrey, UK) set to cut at 100 mm intervals and the finely minced tissue was transferred to a digestion mix consisting of serum-free Dulbecco's modified Eagle's medium media containing 4 mg/ml collagenase A, 4 mg/ml collagenase B, 4 mg/ml dispase and 0.25 mg/ml hyaluronidase (all enzymes purchased from Roche, Mississauga, Ontario, Canada) for 90 min at 37 1C under rocking. Cells were then pelleted by centrifugation and incubated for 4 min in 0.25% trypsin/EDTA (Wisent, St Bruno, Quebec, Canada) at 37 1C and then with DNase for an additional 2 min at room temperature in phosphate-buffered saline containing 2% fetal bovine serum. After centrifugation, cells were resuspended in Dulbecco's modified Eagle's medium containing NH 4 Cl, incubated for 3 min at room temperature and subsequently diluted with phosphate-buffered saline containing 2% fetal bovine serum. Clumped cells were removed by filtering cells on a 70 mm cell strained. Cells were then spun and resuspended in phosphate-buffered saline containing 2% fetal bovine serum to get a final cellular concentration of 5 Â 10 6 cells per ml.
PCR PCR analysis of Cre-mediated excision was performed on total genomic DNA prepared from tail, mammary gland or tumor tissues collected from the different generated mice using a standard protocol. PCR primer sequences and amplification parameters were described elsewhere (Terpstra et al., 2003; Troussard et al., 2003) .
Immunoblot analyses
Flash-frozen tumor pieces were prepared in phospholipase-C-g lysis buffer (Dankort et al., 2001) . Protein amounts were quantified by DC Protein (Bio-Rad, Mississauga, Ontario, Canada). Tumor cell lysates were analyzed by immunoblot. Blots were incubated with horseradish peroxidase-conjugated secondary antibodies (Jackson Laboratories) and visualized by enhanced chemiluminescence (Amersham, Baie d'urfe, Quebec, Canada).
Reverse-phase protein lysate microarray Reverse-phase protein microarray was performed as described previously and used to evaluate the expression and the phosphorylation of 40 distinct proteins (Tibes et al., 2006; Hennessy et al., 2007) .
Three-dimensional invasion assay
Primary cells were prepared from MMTV-Neu-derived mouse mammary tumors by disaggregation in collagenase I and differential centrifugation, as described previously for various mouse mammary tumor cell types (White et al., 2004) . The cells were grown for 2 days on 2-3 mm Matrigel (11.8 mg/ml) (BD Biosciences) to establish multicellular acini. After 2 days a 1-2 mm layer of bovine skin-derived collagen I (at 2.3 mg/ml) (PureCol; Inamed, Nutacon BV, Leimuiden, The Netherlands) was overlayed on top of the Matrigel-embedded acini. For ILK inhibition, we pre-incubated culture with 10 mM QLT0267 for 30 min before addition of collagen I. QLT0267 was subsequently included in the growth media and collagen I gel. For hematoxylin/eosin staining, we fixed cultures overnight in buffered formalin, then paraffin-embedded and sectioned them at 3 mm. TUNEL assay for apoptosis was performed according to manufacturer's instructions for the Apoptag kit (Chemicon, Temecula, CA, USA).
shRNA-mediated ILK knockdown pLK0.1 lentivirus vectors expressing independent shRNA sequences targeting murine ILK were purchased from Open Biosystems (Huntsville, AL, USA). Clone ID for five independent shRNA sequences are the following: TRCN0000022-514, TRCN0000022515, TRCN0000022516, TRCN0000022-517 and TRCN0000022518. Before use in three-dimensional cultures, cells stably expressing the shRNA sequences were established by selection in puromycin, followed by confirmation of ILK protein knockdown by western blot analysis (Supplementary Figure S5) .
Statistical analysis
Kaplan-Meier analysis was used to analyze mouse tumor onsets.
